Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) PT at $27.67

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $27.6667.

ELAN has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Leerink Partners boosted their target price on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, KeyCorp boosted their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ELAN. NewEdge Advisors LLC raised its holdings in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares during the last quarter. SJS Investment Consulting Inc. raised its holdings in Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the last quarter. Huntington National Bank raised its holdings in Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares during the last quarter. Root Financial Partners LLC raised its holdings in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health during the fourth quarter worth $41,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 0.2%

Elanco Animal Health stock opened at $22.77 on Friday. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $27.72. The firm’s fifty day moving average is $24.48 and its 200 day moving average is $22.90. The company has a market capitalization of $11.32 billion, a PE ratio of -47.43, a PEG ratio of 2.94 and a beta of 1.88.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the company earned $0.14 EPS. Elanco Animal Health’s quarterly revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, sell-side analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.